Advice

following a resubmission:

aflibercept (Zaltrap®) is accepted for use within NHS Scotland.

Indication under review: in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy, aflibercept is indicated in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.

In one randomised, double-blind, phase III study, aflibercept plus FOLFIRI chemotherapy regimen resulted in statistically significant longer overall survival compared with placebo plus FOLFIRI chemotherapy regimen.   However the effect was of relatively modest clinical benefit.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of aflibercept. This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

Download detailed advice155KB (PDF)

Download

Medicine details

Medicine name:
aflibercept (Zaltrap)
SMC ID:
878/13
Indication:
In combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy, aflibercept is indicated in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.
Pharmaceutical company
Sanofi-Aventis
BNF chapter
Malignant disease and immunosuppression
Submission type
Resubmission
Status
Accepted
Date advice published:
10 March 2014